Strs Ohio Sells 1,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Strs Ohio lessened its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 5.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,300 shares of the company’s stock after selling 1,900 shares during the quarter. Strs Ohio’s holdings in Kiniksa Pharmaceuticals were worth $584,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in KNSA. IFP Advisors Inc bought a new position in Kiniksa Pharmaceuticals during the third quarter worth about $65,000. Linden Thomas Advisory Services LLC increased its position in shares of Kiniksa Pharmaceuticals by 100.0% during the 3rd quarter. Linden Thomas Advisory Services LLC now owns 115,891 shares of the company’s stock valued at $2,013,000 after purchasing an additional 57,942 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Kiniksa Pharmaceuticals by 13.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 146,568 shares of the company’s stock valued at $2,546,000 after buying an additional 17,790 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in Kiniksa Pharmaceuticals by 89.5% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 55,047 shares of the company’s stock worth $956,000 after buying an additional 26,002 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $777,000. Institutional investors own 53.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on KNSA. Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday. TheStreet raised Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Finally, Evercore ISI raised their target price on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday.

Insider Activity

In related news, CAO Michael R. Megna sold 5,126 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares in the company, valued at approximately $383,242.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 5,582 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $21.00, for a total transaction of $117,222.00. Following the completion of the sale, the chief executive officer now directly owns 65,012 shares in the company, valued at approximately $1,365,252. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Michael R. Megna sold 5,126 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total value of $111,695.54. Following the sale, the chief accounting officer now owns 17,588 shares of the company’s stock, valued at $383,242.52. The disclosure for this sale can be found here. Insiders sold 33,109 shares of company stock worth $709,929 over the last three months. 54.23% of the stock is currently owned by corporate insiders.

Kiniksa Pharmaceuticals Trading Up 1.5 %

Shares of Kiniksa Pharmaceuticals stock opened at $17.88 on Friday. The company’s fifty day simple moving average is $19.27 and its two-hundred day simple moving average is $18.00. The company has a market cap of $1.26 billion, a P/E ratio of 162.55 and a beta of 0.27. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $10.65 and a 12-month high of $22.09.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 23rd. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.11). The company had revenue of $79.90 million for the quarter, compared to analysts’ expectations of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.32%. The firm’s revenue for the quarter was up 65.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.18) earnings per share. Analysts predict that Kiniksa Pharmaceuticals, Ltd. will post 0.06 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.